Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM1A | O60341 | 2/20 | 0.35 |
| ▸ | CCR5 | P51681 | 2/20 | 0.35 |
| ▸ | ALOX5 | P09917 | 4/20 | 0.35 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.33 |
| ▸ | MMP8 | P22894 | 2/20 | 0.33 |
| ▸ | MMP3 | P08254 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.32 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.32 |
| ▸ | AGTR2 | P50052 | 1/20 | 0.32 |
| ▸ | RIPK1 | Q13546 | 1/20 | 0.32 |
| ▸ | MEN1 | O00255 | 1/20 | 0.32 |
| ▸ | TP53 | P04637 | 1/20 | 0.32 |
| ▸ | TSHR | P16473 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4273353 | 0.84 | LMNA (0.39) | KDM1ASMN1; SMN2AGTR2 | |
| SCHEMBL4270118 | 0.81 | RAB9A (0.38) | KDM1ASMN1; SMN2 | |
| SCHEMBL13572502 | 0.70 | LMNA (0.38) | SMN1; SMN2RIPK1 | |
| SCHEMBL4197420 | 0.68 | SMN1; SMN2 (0.46) | KMT2ASMN1; SMN2MEN1TP53 | |
| SCHEMBL4049868 | 0.67 | SMN1; SMN2 (0.41) | KMT2ASMN1; SMN2MEN1TSHR | |
| SCHEMBL4206478 | 0.66 | POLB (0.39) | KMT2ASMN1; SMN2RIPK1MEN1 | |
| SCHEMBL4049772 | 0.65 | RIPK1 (0.37) | RIPK1TSHR | |
| SCHEMBL4206967 | 0.65 | RIPK1 (0.37) | RIPK1TSHR | |
| SCHEMBL754438 | 0.64 | ALDH1A1 (0.43) | KMT2AMEN1 | |
| SCHEMBL4048593 | 0.63 | SMN1; SMN2 (0.41) | KMT2ASMN1; SMN2MEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | MERCK SHARP & DOHME CORP. | 2009-12-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090312335-A1 | Hiv Integrase Inhibitors | RECQL, TYMP, POLR2H | KDM1A 607/4885CCR5 384/4885ALOX5 3742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.